Quantcast

Latest Amgen Stories

2014-03-20 08:29:33

SAN DIEGO, March 20, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran William Ringo has joined its board of directors. "Bill has excellent experience in developing and driving strategies that have enabled success for both large pharmaceutical companies and start-up biotechs. Bill's experience and guidance will be extremely helpful as we enter a transformational year in the development of each of our programs and chart...

2014-03-19 08:25:57

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, March 19, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Amgen, Inc. (NASDAQ: AMGN), Zimmer Holdings, Inc. (NYSE: ZMH), Covidien plc (NYSE: COV), Laboratory Corporation of America Holdings (NYSE: LH), and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership,...

2014-03-17 08:30:17

Study Meets Primary Endpoint of LDL Cholesterol Reduction THOUSAND OAKS, Calif., March 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C). The percent reduction in LDL-C, or "bad" cholesterol, was clinically meaningful and statistically...

2014-03-14 16:23:20

Data Showed Tumor Shrinkage in Both Injected and Metastasized Tumors THOUSAND OAKS, Calif., March 14, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts of the body. The analysis recorded tumor-level responses from a pivotal Phase 3 study evaluating...

2014-03-11 23:00:21

ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Epoetin Alfa Market, 2009-2018” to its store. Dallas, TX (PRWEB) March 12, 2014 Epoetin alfa refers to erythropoietin (EPO), a hormonelike substance secreted by kidney and liver that stimulates erythropoiesis. Indications of EOP approved in China are renal anemia, anemia after chemotherapy and surgery perioperative red blood cell mobilization. The ratio between EPO used in renal dialysis and in...

2014-03-11 04:21:19

WHIPPANY, N.J., THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 11, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR(®) (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not...

2014-03-05 16:26:34

THOUSAND OAKS, Calif., March 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the second quarter of 2014. The dividend will be paid on June 6, 2014, to all stockholders of record as of the close of business on May 15, 2014. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering...

2014-03-01 16:20:28

THOUSAND OAKS, Calif., March 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 34(th) Annual Healthcare Conference at 2:10 p.m. ET on Monday, Mar. 3, 2014, at the Boston Marriott Copley Place in Boston. Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of...

2014-02-25 23:24:42

MarketOptimizer.org offers “PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022” research report in its store. Dallas, TX (PRWEB) February 25, 2014 Switch to Anabolics Driving Osteoporosis Market Growth A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic drugs will prove the key driver in the global osteoporosis market. The new report* forecasts that the combined osteoporosis therapeutics market of the...

2014-02-21 16:23:04

THOUSAND OAKS, Calif., Feb. 21, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the RBC Capital Markets' Global Healthcare Conference at 4:05 p.m. ET on Wednesday, Feb. 26, 2014, at the New York Palace Hotel in New York City. Arvind Sood, vice president of Investor Relations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related